Supplemental material

A

Cumulative Incidence of Symptom Resolution, %

Follow Up Days

57.7%
45.5%

Difference in symptom-free days between breakthrough versus non-breakthrough groups: 2.74 d (95% CI, 0.52-4.96; \( P = 0.0154 \))

Line Color

Breakthrough
Non-breakthrough

Number at risk

Legend

164 156 136 104 102 92 89
116 109 83 62 60 50 46

Follow Up Days

B

Cumulative Incidence of Symptom Resolution, %

Follow Up Days

9.9 days

C

Cumulative Incidence of Symptom Resolution, %

Follow Up Days

7.2 days